SynthesisTargeted oncology2026
Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.
Synthesis in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPARP inhibitor (PARPi)-based therapy is a well-established treatment modality for metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) deficiencies. However, its clinical efficacy in mCRPC without HRR alterations remains undefined.
objectiveThis study aimed to evaluate the efficacy of PARPis in HRR-proficient mCRPC.
methodsA systematic database search was conducted to identify clinical trials evaluating the efficacy of PARPi-based therapies in patients with HRR-proficient mCRPC. Searches were performed using PubMed, Embase Cochrane Library, Web of Science, and relevant international conference proceedings. Both single-arm and pairwise meta-analytical approaches were employed to assess the efficacy of PARPis in HRR-proficient mCRPC, while concurrently comparing the estimates with those from HRR-deficient populations within the same trials.
resultsA total of eight single-arm trials and eight randomized controlled trials were included, comprising 3314 patients, of whom 1727 were HRR-proficient. In the single-arm meta-analysis, the pooled prostate-specific antigen (PSA) response (≥ 50% decrease from baseline) rate was 18% (95% CI 9-29, I
conclusionsThe use of PARPis in the treatment of CRPC demonstrated a significant improvement in PFS irrespective of HRR status. Even in the HRR-proficient subpopulation, PARPi-based therapy conferred encouraging PFS benefits, underscoring its potential clinical relevance beyond HRR-deficient settings. Further biomarker analyses are warranted to refine patient selection and optimize therapeutic strategies.
Indexed as
Identifiers
41335286What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.